Skip to search formSkip to main contentSkip to account menu

FCE 21336

Known as: FCE-21336 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (5)

Antineoplastic AgentsAntiparkinson AgentsDopamine AgonistsErgolines
Galastop

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1985
1985
Antitumor activity of FCE 21336, a new prolactin lowering drug, on the MXT mouse mammary carcinoma.
1984
1984
Combined and sequential treatment using FCE 21336, a new prolactin-lowering drug, and medroxyprogesterone acetate (MPA) in DMBA-induced tumors in rats.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)